Duaklir®

COMBINATIONS (DUO)

LONG-ACTING MUSCARINIC ANTAGONIST + LONG-ACTING BETA-2 AGONIST (LAMA + LABA)

  • Class

    • Long-acting muscarinic antagonist (LAMA)
      Long-acting beta-2 agonist (LABA)

  • Active ingredient

    • Aclidinium bromide


    • Formoterol fumarate dihydrate

  • Device

  • Age

    • 18 +
  • Typical use

    • Asthma (off-label)
      in addition to an ICS, when uncontrolled on high dose ICS + LABA

    Asthma management principles
    • COPD
      uncontrolled on 1 bronchodilator (LAMA or LABA)

    COPD management principles
  • Marketed strength

    • 400/12 mcg
  • Number of doses

    • 60 doses
  • Dose indicator

    • Yes | Indicator
  • Usual adult dosage

    • 1 inh BID

  • Usual pediatric dosage

    • -

  • Required inspiratory flow

    • > 40 - 45 L/min
      Medium internal resistance (R3)

    Inspiratory flows
  • Public coverage

    • MN – NIHB – QC | Open/Regular Benefit
      All provinces except MN – NIHB | Restricted Benefit with criteria
      QC | Not a Benefit 

    Provincial coverage criteria
  • Advantages

    • Less anticholinergic side effects
    • Easy handling
    • Impossible to take empty (locking mechanism)
  • Disadvantages

    • Taste that can be unpleasant
    • BID dosing
    • May fail to actuate despite good inspiratory flow
    Side effects

Product monograph

Download

Search for other inhalers